News | Published:

CRISPR target prediction remains blunt tool for clinical applications

Nature Biotechnologyvolume 37pages204205 (2019) | Download Citation

Subjects

Computational approaches to predict gene editing repair by CRISPR endonucleases remain a work in progress.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 20 March 2019

    In the version of this article initially published, we reported that Sangamo’s SB-318 had failed to change baseline leukocyte α-l-iduronidase in a phase 1/2 trial. The drug failed to change baseline plasma α-l-iduronidase but did increase leukocyte α-l-iduronidase to within the normal range. The error has been corrected in the HTML and PDF versions of the article.

Author information

Affiliations

  1. Cambridge, UK

    • John Hodgson

Authors

  1. Search for John Hodgson in:

Corresponding author

Correspondence to John Hodgson.

About this article

Publication history

Published

Issue Date

DOI

https://doi.org/10.1038/s41587-019-0057-7

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing